Judicial Panel on Multidistrict Litigation (JPML) to create a separate MDL for vision loss lawsuits, rather than merging them into the existing federal MDL for stomach paralysis and gastroparesis claims
As of October 2024, a handful of these products are in late-phase clinical trials, with active ingredients such as retatrutide, survodutide and ecnoglutide, and more than 18 other drug candidates are in earlier stages of development
Its side effects reflect that reality
Health economists estimate it could add approximately $2.76 billion to overall Wegovy sales by 2030, with its share growing from about 3% in 2026 to 17% by 2031
Our role is to help you understand your options clearly and guide you toward the safest, most sustainable solution for your health
To curb costs, plans have restricted coverage or stopped it entirely